More importantly, the 3 genes have been previously used as part of the reported type I Interferon signature in patients with multiple systemic autoimmune diseases (6, 15, 16, 37), as well as to determine response in clinical trials of IFN-α blockade in SLE (35). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.